
AS2863619
CAS No. 2241300-51-4
AS2863619( —— )
Catalog No. M21957 CAS No. 2241300-51-4
AS2863619 is an orally active?inhibitor of cyclin-dependent kinase 8 (CDK8) and CDK19 (IC50s of 0.61 nM and 4.28 nM, respectively).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 170 | Get Quote |
![]() ![]() |
5MG | 260 | Get Quote |
![]() ![]() |
10MG | 410 | Get Quote |
![]() ![]() |
25MG | 678 | Get Quote |
![]() ![]() |
50MG | 954 | Get Quote |
![]() ![]() |
100MG | 1287 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameAS2863619
-
NoteResearch use only, not for human use.
-
Brief DescriptionAS2863619 is an orally active?inhibitor of cyclin-dependent kinase 8 (CDK8) and CDK19 (IC50s of 0.61 nM and 4.28 nM, respectively).
-
DescriptionAS2863619 is an orally active?inhibitor of cyclin-dependent kinase 8 (CDK8) and CDK19 (IC50s of 0.61 nM and 4.28 nM, respectively).
-
In VitroAS2863619 (1 μM; 22 hours; mouse CD4+ T cells) treatment suppresses serine phosphorylation of the PSP motif of STAT5b to ~40% while enhancing tyrosine phosphorylation in the C-terminal domain to ~160% of control-treated samples. Western Blot Analysis Cell Line:Mouse CD4+ T cells Concentration:1 μM Incubation Time:22 hours Result:Suppressed serine phosphorylation of the PSP motif of STAT5b to ~40% while enhancing tyrosine phosphorylation in the C-terminal domain to ~160% of control-treated samples.
-
In VivoAS2863619 (30 mg/kg; oral administration; daily; for 2 weeks; mice) treatment after sensitization with 2,4-dinitrofluorobenzene (DNFB) dampens the degree of the secondary response, with milder infiltration of inflammatory cells into the skin and decreases ratios of interferon-γ+ (IFN-γ+) cells in a skin contact hypersensitivity model,when compared with vehicle-treated control mice. Treg depletion before the elicitation of the secondary response abolishes AS2863619-induced suppression. KLRG1+ Foxp3+ T cells are specifically increased in DNFB sensitized AS2863619-treated mice. Animal Model:Mice with DNFB-induced contact skin hypersensitivity Dosage:30 mg/kg Administration:Oral administration; daily; for 2 weeks Result:The degree of the secondary response, with milder infiltration of inflammatory cells into the skin and decreased ratios of interferon-γ+ (IFN-γ+) cells.
-
Synonyms——
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorSTAT5|CDK8|CDK19
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2241300-51-4
-
Formula Weight405.24
-
Molecular FormulaC16H14Cl2N8O
-
Purity>98% (HPLC)
-
SolubilityDMSO:245 mg/ml(604.58 mM; Need ultrasonic)
-
SMILESCl.Cl.Cc1nc2ccc(cc2[nH]1)-n1c(nc2cnccc12)-c1nonc1N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Akamatsu M, et al. Conversion of antigen-specific effector/memory T cells into Foxp3-expressing Treg cells by inhibition of CDK8/19. Sci Immunol. 2019 Oct 25;4(40). pii: eaaw2707.
molnova catalog



related products
-
STAT5-IN-1
A selective, small molecule inhibitor of the transcription factor STAT5 with IC50 of 47±17 uM in FP assays.
-
Corosolic acid
Corosolic acid contains anti-angiogenic activity that can suppress FAK signaling induced by angiopoietin-1.
-
HJC0152
A potent, orally bioavailable STAT3 signaling inhibitor that exhibits promising antitumor effects in vitro and in vivo.